Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891997351> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2891997351 abstract "e21001 Background: Efficacy of Vb in the treatment of mm has been established. We aimed to analyze characteristics of pts achieving LTR to Vb in order to identify potential predictive factors of prolonged benefit. Methods: We collected information about pts affected by BRAF V600 mutated mm treated with Vb at Medical Oncology Unit of Istituto Nazionale dei Tumori, Milan, Italy, from 09/2010 to 08/2014. LTR was defined as clinical or radiological benefit longer than 14 months (mos). Biological data about circulating lymphocyte subpopulations and CCL2 levels were also determined. Results: 46 pts (26 men, 20 women) were identified. Median age was 58 years. ECOG performance status was 0 in 44 pts. Disease stage was M1a in 14 pts, M1c in 20 pts. 8 pts had high serum LDH levels and 5 brain metastases at baseline. 41 pts harbored BRAF V600E mutation, 5 V600K. Median follow up was 47 mos. 5 pts had received adjuvant interferon; 9 pts had been treated with up to 3 lines for metastatic disease (either chemotx or ipilimumab). According to RECIST 1.1, 22% of pts showed complete response (CR), 50% partial response and 22% stable disease. Notably, all CRs were maintained for more than 2 years. 26 pts progressed, mostly (38%) with brain metastases; 16 of them continued tx beyond progression. Median duration of response was 33 mos, being significantly longer in M1a than in M1c (44 versus 28 mos). Median PFS was 32.5 mos; median OS was not reached. All pts experienced at least 1 adverse event (AE); the AEs were moderate or severe in 22% of cases. 19 pts underwent dose reduction, but no discontinuation due to AEs was observed. After 6 mos of tx, pts with LTRs had less myeloid derived suppressor cells (CD11b+ CD14+) and more memory Th1 cells (CD8+ CXCR3+) if compared with pts not bearing LTRs. The same pts after 1 mo of tx showed lower plasma levels of CCL2, a marker of acquired resistance to Vb. Conclusions: Vb can induce LTRs in a subset of pts with mm also in presence of unfavorable prognostic factors, though M1a pts are more likely to obtain prolonged benefit. Toxicity is frequent, but manageable with limited dose reductions. Exploratory biological analyses suggest an immunomodulatory effect of Vb and the existence of circulating biomarkers of LTR." @default.
- W2891997351 created "2018-09-27" @default.
- W2891997351 creator A5000391768 @default.
- W2891997351 creator A5005810267 @default.
- W2891997351 creator A5027729250 @default.
- W2891997351 creator A5032506137 @default.
- W2891997351 creator A5069765350 @default.
- W2891997351 creator A5073843172 @default.
- W2891997351 creator A5074487260 @default.
- W2891997351 creator A5082780385 @default.
- W2891997351 creator A5084233190 @default.
- W2891997351 creator A5090903194 @default.
- W2891997351 date "2017-05-20" @default.
- W2891997351 modified "2023-09-25" @default.
- W2891997351 title "Retrospective analysis of patients (pts) with metastatic melanoma (MM) showing long-term response (LTR) to vemurafenib (Vb)." @default.
- W2891997351 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e21001" @default.
- W2891997351 hasPublicationYear "2017" @default.
- W2891997351 type Work @default.
- W2891997351 sameAs 2891997351 @default.
- W2891997351 citedByCount "0" @default.
- W2891997351 crossrefType "journal-article" @default.
- W2891997351 hasAuthorship W2891997351A5000391768 @default.
- W2891997351 hasAuthorship W2891997351A5005810267 @default.
- W2891997351 hasAuthorship W2891997351A5027729250 @default.
- W2891997351 hasAuthorship W2891997351A5032506137 @default.
- W2891997351 hasAuthorship W2891997351A5069765350 @default.
- W2891997351 hasAuthorship W2891997351A5073843172 @default.
- W2891997351 hasAuthorship W2891997351A5074487260 @default.
- W2891997351 hasAuthorship W2891997351A5082780385 @default.
- W2891997351 hasAuthorship W2891997351A5084233190 @default.
- W2891997351 hasAuthorship W2891997351A5090903194 @default.
- W2891997351 hasConcept C126322002 @default.
- W2891997351 hasConcept C143998085 @default.
- W2891997351 hasConcept C167135981 @default.
- W2891997351 hasConcept C2776131300 @default.
- W2891997351 hasConcept C2777658100 @default.
- W2891997351 hasConcept C2994587330 @default.
- W2891997351 hasConcept C502942594 @default.
- W2891997351 hasConcept C71924100 @default.
- W2891997351 hasConceptScore W2891997351C126322002 @default.
- W2891997351 hasConceptScore W2891997351C143998085 @default.
- W2891997351 hasConceptScore W2891997351C167135981 @default.
- W2891997351 hasConceptScore W2891997351C2776131300 @default.
- W2891997351 hasConceptScore W2891997351C2777658100 @default.
- W2891997351 hasConceptScore W2891997351C2994587330 @default.
- W2891997351 hasConceptScore W2891997351C502942594 @default.
- W2891997351 hasConceptScore W2891997351C71924100 @default.
- W2891997351 hasLocation W28919973511 @default.
- W2891997351 hasOpenAccess W2891997351 @default.
- W2891997351 hasPrimaryLocation W28919973511 @default.
- W2891997351 isParatext "false" @default.
- W2891997351 isRetracted "false" @default.
- W2891997351 magId "2891997351" @default.
- W2891997351 workType "article" @default.